What Isomorphic Labs does
Isomorphic Labs is an AI-first drug design and development company building an end-to-end “drug design engine” intended to accelerate and improve how medicines are discovered, designed, and developed. The company’s core positioning is that modern AI models—used “in silico” for faster iteration and better predictive accuracy—can help teams probe biological systems and chemical space more efficiently than traditional, bench-heavy workflows.
Strategically, Isomorphic Labs is structured around (1) a unified computational engine for drug design, (2) internal and partner-driven drug discovery programs across multiple therapeutic areas and modalities, and (3) scaling efforts supported by large external capital infusions and high-profile pharmaceutical collaborations. The company emphasizes that its platform extends beyond structure prediction alone (associated with AlphaFold) toward predicting multiple properties required for drug design decisions, including binding/interaction-relevant capabilities and generalization to novel biomolecular contexts.
Business model-wise, Isomorphic Labs combines partnered discovery programs with larger platform development efforts. It publicly highlights strategic research collaborations with pharmaceutical partners such as Novartis, Eli Lilly, Johnson & Johnson, and related program expansion announcements. In parallel, it runs wholly owned internal programs, with internal focus areas stated as oncology and immunology.
Current strategic position (as of 2026-09-12): Isomorphic Labs has recently disclosed a major Series B capital raise and continued platform progress toward deploying its drug design engine “at scale,” while also publishing ongoing technical updates on its unified IsoDDE system and expanding/maintaining multi-year collaborations with major industry partners.